科济药业2025:亏损收窄87%,实体瘤CAR-T冲刺上市

药智网
Mar 09

作为中国CAR-T细胞治疗领域的领军企业,科济药业在2025年实现了商业化产品的快速放量、研发管线的重大突破以及财务状况的显著改善,展现出从Biotech向BioPharma转型的强劲动能。2025年,科济药业实现收益约1.26亿元,这一增长主要来源于其核心商业化产品赛恺泽的销售。财务结构方面,公司毛利约为8000万元,得益于自主生产的质粒及病毒载体产出稳定、批次产量高,彰显了强大的成本竞争优势。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10